Alert: Negative Investment/Fundamental Signals (4/3/24)-Neurocrine Biosciences Inc (NASDAQ: NBIX)


Extremely important negative changes in investment behavior have recently occurred for Neurocrine Biosciences Inc (NASDAQ: NBIX): negative upside/downside volume developed, and its shorter term price trend turned down.

Neurocrine Biosciences Inc (NASDAQ: NBIX). Significant negative changes in fundamentals have recently occurred: the consensus estimate for December, 2025 decreased significantly, and significant quarterly earnings deceleration occurred.

In light of these highly negative signals we are reviewing our current Overall Rating of B. We would view the shares with caution pending completion of this review in the next several days.


Current PriceTarget Research Rating

With future capital returns forecasted to be above the cost of capital, NBIX is expected to continue to be a major Value Builder.

Neurocrine Biosciences has a current Value Trend Rating of B (Positive). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. Neurocrine Biosciences has a neutral Appreciation Score of 44 but a very high Power Rating of 86, leading to the Positive Value Trend Rating.

Recent Price Action

Neurocrine Biosciences Inc (NASDAQ: NBIX) stock declined slightly by -0.1% on 4/3/24. The stock closed at $137.59. However, trading volume in this decline was below average at 67% of normal. The stock has been exceptionally strong relative to the market over the last nine months but has declined -1.9% during the last week.

Be the first to comment

Leave a Reply

Your email address will not be published.